Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients. It works by modulating the immune system and inhibiting angiogenesis, providing clinical benefit in these hematologic cancers.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and offers reliable logistics to support treatment programs across Europe, Asia, Africa and the Americas.

Lenalidomide is used in hematologic malignancies and related bone marrow disorders, targeting disease pathways that involve abnormal plasma cells and dysplastic hematopoiesis. - Multiple Myeloma: improves progression‑free survival and overall response rates in relapsed or newly diagnosed patients. - Multiple Myeloma (maintenance): prolongs remission duration after initial therapy. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves blood counts.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Neutropenia - Fatigue - Diarrhea - Rash Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe infections, including opportunistic pathogens - Second primary malignancies

Patients receiving Lenalidomide should be monitored closely for safety concerns. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Thromboembolism risk assessment: evaluate patient history and consider prophylactic anticoagulation. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Renal and hepatic function: adjust use based on organ function assessments. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with several medicines; awareness of major and moderate interactions helps optimize safety. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (warfarin): heightened risk of bleeding. - Live vaccines: risk of infection due to immunosuppression. - Pregnancy‑category teratogenic agents: additive teratogenic risk. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal toxicity. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure.